As briefly stated elsewhere in this article, SGLT2 inhibition has yielded remarkable effects on cardiovascular (particularly HF) and kidney outcomes in large clinical trials (Fig. 1).8–10,56,71,72 These results were confirmed in cardiovascular safety trials in patients with T2D and established CVD or at high risk for cardiovascular events in the DECLARE-TIMI 5856 and CANVAS9 studies, which also demonstrated improvement in HF outcomes without previous documented HF or established CVD at baseline. This evidence concerns the gene SLC5A2 and hydrops fetalis.